TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inmune Bio ( (INMB) ) just unveiled an announcement.
On December 1, 2025, INmune Bio Inc. announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595, presented at the Clinical Trials on Alzheimer’s Disease conference. The data, which showed a trend towards slowed neurodegeneration in patients with early Alzheimer’s disease and high inflammatory burden, reinforce XPro1595’s potential as a promising therapy for inflammation-driven Alzheimer’s, a large unmet market need.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting innate immune dysfunction to combat diseases. The company’s pipeline includes CORDStrom™, a mesenchymal stromal cell platform, the DN-TNF Platform (XPro™/XPro1595) for neuroinflammatory and neurodegenerative conditions, and INKmune™, designed to prime natural killer cells to eliminate minimal residual disease in cancer.
Average Trading Volume: 457,214
Technical Sentiment Signal: Sell
Current Market Cap: $49.98M
Find detailed analytics on INMB stock on TipRanks’ Stock Analysis page.